ORMP - Oramed Pharmaceuticals Inc Stock Price, Fair Value and News

$2.37-0.12 (-4.82%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ORMP Price Action

Last 7 days

-4.0%

Last 30 days

4.9%

Last 90 days

2.6%

Trailing 12 Months

1.3%

ORMP RSI Chart

ORMP Valuation

Market Cap

95.5M

Price/Earnings (Trailing)

21.4

Price/Sales (Trailing)

71.9

EV/EBITDA

11.8

Price/Free Cashflow

-12.05

ORMP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORMP Fundamentals

ORMP Revenue

Revenue (TTM)

1.3M

ORMP Earnings

Earnings (TTM)

4.5M

Earnings Growth (Yr)

-508.91%

Earnings Growth (Qtr)

-312.97%

ORMP Profitability

Operating Margin

93.28%

EBT Margin

174.70%

Return on Equity

2.85%

Return on Assets

2.7%

Free Cashflow Yield

-8.3%

ORMP Investor Care

Buy Backs (1Y)

0.07%

Diluted EPS (TTM)

0.11

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.9M	2.2M	1.5M	1.3M
2022	2.8M	2.5M	2.5M	1.7M
2021	2.9M	2.9M	2.7M	2.8M
2020	2.7M	2.7M	2.7M	2.7M
2019	2.6M	2.6M	2.7M	2.7M
2018	2.5M	2.5M	2.4M	2.5M
2017	1.5M	2.0M	2.5M	2.5M
2016	0	0	641.0K	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

CEO	Mr. Nadav Kidron Esq.
WEBSITE	oramed.com
SECTOR	Healthcare
INDUSTRY	Biotechnology

Oramed Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Oramed Pharmaceuticals Inc? What does ORMP stand for in stocks?

ORMP is the stock ticker symbol of Oramed Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oramed Pharmaceuticals Inc (ORMP)?

As of Fri Dec 20 2024, market cap of Oramed Pharmaceuticals Inc is 95.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORMP stock?

You can check ORMP's fair value in chart for subscribers.

Is Oramed Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORMP is over valued or under valued. Whether Oramed Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Oramed Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORMP.

What is Oramed Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ORMP's PE ratio (Price to Earnings) is 21.4 and Price to Sales (PS) ratio is 71.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oramed Pharmaceuticals Inc's stock?

In the past 10 years, Oramed Pharmaceuticals Inc has provided -0.066 (multiply by 100 for percentage) rate of return.